Amneal Pharmaceuticals (AMRX) is recalling three lots of sulfamethoxazole/trimethoprim tablets due to microbial contamination, the US Food and Drug Administration said Wednesday.
The recall was issued after a product quality complaint over the appearance of black spots on the tablet surface, the FDA said.
The lots in question were distributed nationwide to wholesalers and distributors between December 4, 2024 and May 15, 2025, according to the FDA.
The tablets are used for the treatment of urinary tract infections.
Price: 7.41, Change: -0.04, Percent Change: -0.60
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.